RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA

Oncogene ◽  
2021 ◽  
Author(s):  
C. James Block ◽  
Allison V. Mitchell ◽  
Ling Wu ◽  
James Glassbrook ◽  
Douglas Craig ◽  
...  
2010 ◽  
Author(s):  
Ulus Atasoy ◽  
Matthew Gubin ◽  
Bob Calaluce ◽  
Wade Davis ◽  
Joseph Magee ◽  
...  

2011 ◽  
Author(s):  
Patsharaporn Techasintana ◽  
Matthew Michael Gubin ◽  
Joseph David Magee ◽  
Garrett MacKenzie Dahm ◽  
Ulus Atasoy

Cell Cycle ◽  
2010 ◽  
Vol 9 (16) ◽  
pp. 3357-3366 ◽  
Author(s):  
Matthew M Gubin ◽  
Robert Calaluce ◽  
Justin Wade Davis ◽  
Joseph D Magee ◽  
Connie S. Strouse ◽  
...  

eLife ◽  
2014 ◽  
Vol 3 ◽  
Author(s):  
Sakari Vanharanta ◽  
Christina B Marney ◽  
Weiping Shu ◽  
Manuel Valiente ◽  
Yilong Zou ◽  
...  

The mechanisms through which cancer cells lock in altered transcriptional programs in support of metastasis remain largely unknown. Through integrative analysis of clinical breast cancer gene expression datasets, cell line models of breast cancer progression, and mutation data from cancer genome resequencing studies, we identified RNA binding motif protein 47 (RBM47) as a suppressor of breast cancer progression and metastasis. RBM47 inhibited breast cancer re-initiation and growth in experimental models. Transcriptome-wide HITS-CLIP analysis revealed widespread RBM47 binding to mRNAs, most prominently in introns and 3′UTRs. RBM47 altered splicing and abundance of a subset of its target mRNAs. Some of the mRNAs stabilized by RBM47, as exemplified by dickkopf WNT signaling pathway inhibitor 1, inhibit tumor progression downstream of RBM47. Our work identifies RBM47 as an RNA-binding protein that can suppress breast cancer progression and demonstrates how the inactivation of a broadly targeted RNA chaperone enables selection of a pro-metastatic state.


2020 ◽  
Vol 52 (8) ◽  
pp. 801-809 ◽  
Author(s):  
Jinghua Chen ◽  
Meiqin Zhu ◽  
Liqiu Zou ◽  
Junxian Xia ◽  
Jiacheng Huang ◽  
...  

Abstract The treatment of triple-negative breast cancer (TNBC) relies largely on chemotherapies. However, it is frequent that TNBC patients develop resistance to the chemotherapy drugs. Generation of drug-resistant cell lines facilitates the identification of drug resistance. Here, we established two paclitaxel (PTX)-resistant TNBC cancer cell lines using an intermittent and stepwise method and found that long non-coding RNA long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) was significantly decreased in PTX-resistant cancer cells. Ectopic expression of LINC-PINT sensitized both PTX-resistant TNBC and wild-type TNBC to PTX. Moreover, RNA immunoprecipitation showed that LINC-PINT bound to RNA-binding protein NONO. Overexpression of LINC-PINT resulted in the degradation of NONO in a proteasome-dependent manner and vice versa. Knockdown of NONO with siRNA sensitized TNBC to PTX. We further analyzed the expression level of LINC-PINT and NONO in patient samples via online database and found that LINC-PINT and NONO may function antagonistically in all types of breast cancers. Taken together, our data illustrated a tumor suppressor role of LINC-PINT in sensitizing TNBC to chemotherapies via destabilizing NONO.


Sign in / Sign up

Export Citation Format

Share Document